SLC35G6

Across TCGA pan-cancer cohorts, SLC35G6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC35G6 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLC35G6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC35G6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA and UCEC are the cancer types where SLC35G6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.165	0.924	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC35G6–BRCA (OS)

Open the BRCA breakdown →